舒巴坦-头孢哌酮治疗医院获得性肺炎的效果观察

A CLINICAL OBSERVATION OF SULBACTAM CEFOPERAZONE IN TREATMENT OF NOSOCOMIAL PNEUMONIA

①目的 探讨舒巴坦 头孢哌酮对医院获得性肺炎的效果。②方法 将 6 3例医院获得性肺炎病人随机分为两组 :治疗组 32例 ,采用舒巴坦 头孢哌酮 2 g静脉滴注 ,每 8～ 12h 1次 ;对照组 31例 ,采用头孢噻肟 2 g静脉滴注 ,每 8～ 12h 1次。两组疗程均为 7～ 14d .③结果 治疗组治疗有效率为 87.5 % ,细菌清除率为 86 .7% ;对照组有效率为 83.9% ,细菌清除率为 84 .6 % ,两组比较差异无显著性 (χ2 =0 .15 2 ,0 .184 ,P >0 .0 5 )。两组病人共分离出病原菌 5 6株 ,药敏试验显示对舒巴坦 头孢哌酮敏感率为 89.3% ,高于头孢噻肟的 6 9.6 %和头孢哌酮的6 6 .1% ,差异有显著性 (χ2 =5 .83,5 .4 2 ,P <0 .0 5 )。④结论 舒巴坦 头孢哌酮治疗医院获得性肺炎疗效良好 ,使用安全。

Objective\ To assess the therapeutic efficacy of sulbactam cefoperazone(Sulperazon) in nosocomial pneumonia.\ Methods\ 63 patients were randomly divided into two groups. Treated Group (n =32) was given sulperazon 2 g,iv,drip,q8 h to q12 h; Control Group ( n =31), cefotaxime 2 g,iv,drip,q8 h to q12 h.The course was 7 to 14 days for both groups. Results\ The response rate was 87.5% for Treated Group, and 83.9% for Control Group. The bacterial eradication rate was 86.7% for Treated Group, and 84.6% for Control Group. The difference was not significant between the two groups ( χ 2=0.152,0.184, P >0.05).The rate of clinical isolates sensitive to sulperazon was 89.3%, which was much higher than that of cefotaxime (69.6%) and cefoperazone( 66.1%), the difference being significant ( χ 2=5.83,5.42,P <0.05). \ Conclusion\ Sulperazon is effective and safe in the treatment of nosocomial pneumonia.